Citigroup
TNGX icon

Citigroup’s Tango Therapeutics TNGX Stock Holding History

Citigroup’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.75M Buy
152,007
+132,374
+674% +$3.27M ﹤0.01% 2187
2026
Q1 		$411K Sell
19,633
-16,603
-46% -$231K ﹤0.01% 3660
2025
Q4 		$321K Buy
36,236
+18,134
+100% +$156K ﹤0.01% 3788
2025
Q3 		$152K Sell
18,102
-12,189
-40% -$82.5K ﹤0.01% 4104
2025
Q2 		$155K Sell
30,291
-11,532
-28% -$28.5K ﹤0.01% 4181
2025
Q1 		$57.3K Sell
41,823
-5,169
-11% -$12.7K ﹤0.01% 4845
2024
Q4 		$145K Buy
46,992
+8,316
+22% +$38.6K ﹤0.01% 4630
2024
Q3 		$298K Buy
38,676
+16,611
+75% +$159K ﹤0.01% 4080
2024
Q2 		$189K Sell
22,065
-169,368
-88% -$1.31M ﹤0.01% 3902
2024
Q1 		$1.52M Buy
191,433
+183,270
+2,245% +$1.96M ﹤0.01% 2672
2023
Q4 		$80.8K Buy
8,163
+6,945
+570% +$60.3K ﹤0.01% 4288
2023
Q3 		$13.7K Sell
1,218
-14,910
-92% -$90.9K ﹤0.01% 4480
2023
Q2 		$53.5K Buy
16,128
+7,937
+97% +$28.6K ﹤0.01% 4605
2023
Q1 		$32.4K Sell
8,191
-2,152
-21% -$12.5K ﹤0.01% 4372
2022
Q4 		$75K Sell
10,343
-1,449
-12% -$10.2K ﹤0.01% 4137
2022
Q3 		$43K Sell
11,792
-1,752
-13% -$7.48K ﹤0.01% 4457
2022
Q2 		$61K Sell
13,544
-23,165
-63% -$140K ﹤0.01% 4455
2022
Q1 		$278K Buy
36,709
+4,267
+13% +$37K ﹤0.01% 3887
2021
Q4 		$355K Buy
32,442
+29,273
+924% +$352K ﹤0.01% 4023
2021
Q3 		$41K Buy
+3,169
New +$38K ﹤0.01% 4844

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Citigroup's TNGX Position: Q2 2026 in Review

Citigroup increased its Tango Therapeutics (TNGX) stake by 674% in Q2 2026, buying an estimated $3.27M and bringing the position to 152,007 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2187.

Citigroup first reported a position in TNGX in Q3 2021 and has held it in 20 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Citigroup held 152,007 shares of Tango Therapeutics worth $4.75M as of Q2 2026.
  • Citigroup bought 132,374 Tango Therapeutics shares in Q2 2026, an estimated $3.27M.
  • Tango Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2187 holding.
  • Citigroup first reported a position in Tango Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.